CEO total compensation of approximately $3.4 million in 2025 is well-calibrated for a clinical-stage biotech of Atea's market cap (~$427M), and the company reports that 79% of CEO target pay is at risk, with performance stock awards (which vest only upon achievement of specific regulatory and commercialization milestones over three years) making up more than 50% of the CEO's long-term equity value — satisfying the policy's requirement that at least 50-60% of senior executive pay be variable and performance-based. The annual cash bonus was tied to pre-set, disclosed corporate goals and paid out at 100% of target based on the Compensation Committee's objective assessment of goal achievement with no discretionary adjustments, and stock options deliver value only if the share price rises, further aligning executive and shareholder interests. The company also has a meaningful clawback policy covering both cash and equity incentives triggered by financial restatement, conducts active stockholder engagement, and AVIR's 1-year stock return of +85.5% significantly outperforms the XBI — SPDR S&P Biotech ETF's 1-year return of +66.4%, indicating that the incentive pay structure is working as intended.

KPMG's non-audit fees (tax consulting of $16,200) represent only about 2.4% of audit fees ($688,500), far below the 50% threshold that would raise independence concerns; tenure of approximately 12 years is well below the 25-year threshold; KPMG is a Big 4 firm appropriate for a company of Atea's size; and no material financial restatements were identified.